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The function of c-Myb protein was revealed by transfecting an expression vector containing the entire c-Myb
protein-coding sequence into the murine CTLL-2 T-cell line. Expressions of high levels of c-Myb protein did
not alter the expression of several T-cell markers, c-fos mRNA expression, responses to interleukin-2, and
growth characteristics of these cells. Interestingly, expression of the c-myc gene was drastically increased in this
clone. Further, the c-myb expression plasmid, but not a frameshift mutant of c-myb, enhanced the expression
of a hybrid construct of c-myc promoter linked to a reporter gene by 8- to 14-fold. These results demonstrate
a role of c-Myb protein in c-myc gene expression.
The c-myb proto-oncogene is the cellular homolog of the
transforming v-myb gene of avian myeloblastosis virus,
which causes acute myelomonocytic leukemia in chickens
and transformation of myeloid cells in vitro (22, 29). The
gene is mainly expressed by immature hematopoietic cells.
The c-myb gene encodes a 75-kilodalton nuclear protein that
is associated with the nuclear matrix and exhibits DNA-
binding activity (3, 5, 25, 28, 31). Its viral counterpart, the
v-Myb protein, has an affinity for the sequence pyAACGM
(4). However, the function of both proteins remains unclear.
Existing reports in the literature point to three potential roles
for the c-myb protein: gene regulation, cell differentiation,
and proliferation.
The c-myb gene was initially proposed to be involved in
gene regulation owing to its nuclear location and its ability to
bind DNA (5, 28, 31). Antiserum directed against a portion
of the c-Myb protein is known to inhibit mRNA transcription
in ML-1 human myeloblastic leukemia cells (24). During the
preparation of this manuscript, several groups have shown
by transient cotransfection experiments that c-Myb trans-
activates promoter function. These target promoters include
multiple copies of the simian virus 40 (SV40) enhancer (38),
an artificial promoter of multiple copies of pyAAC(G/T)G
(54), and the hsp70 promoter (29). These results strongly
suggest a transcriptional role for c-Myb; however, the cel-
lular target genes of c-Myb in lymphocytes have not been
identified.
The c-Myb protein is proposed to be important in differ-
entiation because of its differential patterns of expression in
immature and mature differentiated cells (43, 50). Elevated
expression of a transfected c-myb gene in murine erythro-
leukemia cells blocks differentiation normally induced by
dimethyl sulfoxide (7). An antisense oligonucleotide targeted
at the c-myb transcript also interferes with in vitro he-
matopoiesis (19).
Finally, another proposed role for c-Myb is the control of
cell proliferation. Expression of c-myb in T cells is regulated
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in a cell-cycle-dependent manner and may be linked to
stimulation via ligand-receptor interactions (33, 46, 49, 50,
51). Cells treated with interleukin-2 (IL-2) or mitogen ex-
press high levels of c-myb during cell cycle progression and
prior to proliferation (40, 49).
Abnormal expression of c-myb, due to either rearrange-
ment or amplification of the gene, has been observed in a
number of different neoplasias (2, 37, 44, 47, 52). In addition,
elevated expression of the c-myb gene also occurs in an
aberrant CD4- CD8- T-cell population which accumulates
in the lymph nodes of autoimmune lpr mice (16, 36, 56). It
has been suggested that the aberrant lpr T cells resulted from
a defect in thymocyte maturation (56), and the high c-myb
expression is likely to be associated with abnormal T-cell
ontogeny (36).
Due to the crucial roles c-myb may assume, this report
examines the effects of elevated c-myb expression in T
lymphocytes. Our findings showed that the c-Myb protein
can trans-activate the c-myc promoter. These results pro-
vide strong evidence that c-Myb protein regulates the pro-
moter function of c-myc in T-cell lines.
MATERIALS AND METHODS
Cells. The IL-2-dependent CTLL-2 T-cell line (20) was
obtained from the American Type Culture Collection (Rock-
ville, Md.) and cultured in Dulbecco modified Eagle medium
supplemented with 10% fetal bovine serum and containing
either 5% supernatant from phorbol-12-myristate-13-acetate-
stimulated EL-4 cells (17) or a recombinant IL-2 (Amgen,
Thousand Oaks, Calif.). EL-4 is a murine thymoma cell line.
Expression vectors and probes. The pRmb3SVneo expres-
sion vector contains a mouse c-myb cDNA promoted from
the Rous sarcoma virus long terminal repeat (Fig. 1). The
plasmid also contains the SV40 promoter link to the neomy-
cin gene (derived from pSV2neo), which encodes resistance
to the antibiotic G418. The pSV2neo plasmid (48) contains
the SV40 promoter link to the neomycin gene. pM(Bg)CAT
contains a 1.7-kilobase (kb) BglII-BglII fragment of the
murine c-myc 5'-flanking DNA, exon 1, and a portion of the
intron 1 link to the chloramphenical acetyltransferase (CAT)
gene (cat) (41). pCAT(AEP) is the parent plasmid of pM(Bg)
CAT, and it does not have any c-myc sequences. pSV2CAT
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FIG. 1. Structures of the pRmb3SVneo (A) expression plasmid
and the pM(Bg)CAT hybrid plasmid (B). The pRmb3SVneo vector
contains a Rous sarcoma virus long terminal repeat which promotes
transcription of the SmaI-BglII fragment of the entire murine c-myb
coding region. The SV40 promoter was used to drive transcription of
the neomycin gene and is derived from the pSV2neo expression
vector (48). In pM(Bg)CAT, a 1.7-kb BglII (Bg) fragment containing
the c-myc 5'-flanking sequence, exon 1, and a portion of intron 1 was
inserted 5' of the cat gene in pCAT(AEP) (41).
contains the SV40 enhancer-early promoter region linked to
the cat gene (24). pAlOCAT contains the SV40 early pro-
moter linked to the cat gene. Recombinant plasmids contain-
ing c-myc (1) and v-fos (11) and mouse gamma-actin probe
pHF-1 (23) have been described previously. pJTmyb-fs is a
frameshift mutant of pRmb3SVneo. It was produced by
linearization of pRmb3SVneo with BstXI, digestion with
mung bean nuclease, ligation, and transformation into Esch-
erichia coli H5. The resultant plasmid was characterized by
double-stranded DNA sequence determination. The BstXI
site CCATATTTCTGG was mutated to CCAGG with a
7-base-pair deletion.
Antibodies. Anti-CD8 (53-6.7) (32), anti-CD4 (RL 172.4)
(13), anti-Thy-1.2 (AT83) (32), RA3-3A1 (9), RA3-2C2 (8),
9F3 (15), 6C3 (14), anti-IL-2 receptor (34), and anti-CD3
hamster monoclonal antibody (145-2C11) have been de-
scribed. The rabbit anti-c-Myb polyclonal antiserum (5) was
obtained from William J. Boyle, Salk Institute, San Diego,
Calif.
Fluorescence staining and flow cytometric analysis. Fluo-
rescence staining and flow cytometric analysis were per-
formed as described previously (56).
Labeling of cells and immunoprecipitations. Cells were
prepared and lysates were immunoprecipitated as previously
described (16).
Transfection of CTLL-2 cells and selection with G418.
CTLL-2 cells (1 x 107) were transfected by electroporation
with a Bio-Rad gene pulser (45). After transfection, cells
were allowed to recover for 2 days before selection in growth
medium containing 2 mg of the antibiotic G418 (10) (GIBCO
Laboratories, Grand Island, N.Y.) per ml. Transfected cells
were cloned by limiting dilution and were determined to be
clones by calculating the percentage of wells containing cells
growing in selective medium.
Preparation of crude cytoplasmic RNA and dot-blot hybrid-
ization. Cytoplasmic RNA was prepared and screened for
levels of c-myb by dot-blot hybridization as described pre-
viously (55).
RNA isolation and Northern (RNA) hybridization. Total
cellular RNA was prepared from selected clones and North-
ern hybridizations were performed as described previously
(6).
Transient transfection and CAT assays. CTLL-2 and EL-4
cells were grown to the log phase and then transfected with
various plasmids by using the Bio-Rad gene pulser electro-
poration apparatus as previously described (21, 45). CAT
assays were performed as described previously (45). Percent
acetylation was quantified by cutting out sections of the plate
that corresponded to these two forms, followed by scintilla-
tion counting.
Determination of cell doubling times. Transfected clones
were cultured in 24-well plates at 5 x 104 cells per well in 1
ml of growth medium containing 5 units of recombinant IL-2
per ml. Samples were removed every 24 h, and cells were
counted with a Coulter Counter (model ZM; Coulter Elec-
tronics Limited, Hialeah, Fla.). Cell doubling times were
determined from graphs of cell number versus time.
RESULTS
Cells transfected with pRmb3SVneo express high levels of
c-myb RNA. CTLL-2 cells were transfected by electropora-
tion with either the pRmb3SVneo or pSV2neo expression
vector shown in Fig. 1. After selection with the antibiotic
G418, a cytoplasmic dot-blot was used to verify that
pRmb3SVneo transfectants contained abundant c-myb-
specific RNA (10).
The experimental and control transfectants were subse-
quently cloned by limiting dilution. Southern analyses were
performed with DNA extracted from experimental and con-
trol transfectants to ensure that the clones were different.
Finally, the clones were expanded and verified for expres-
sion of c-myb RNA, using dot-blot hybridization as the
screening procedure.
pRmb3SVneo transfectants express c-myb gene product. To
verify that the pRmb3SVneo-transfected clones produced
c-myb mRNA, we subjected purified RNA from several
pRmb3SVneo-transfected clones to Northern analysis. Two
different c-myb transcripts were observed in all the
pRmb3SVneo-transfected clones (Fig. 2). The larger tran-
script (3.8 kb) represents the c-myb message transcribed
from the endogenous gene (44), and it is present in all
samples. The smaller transcript (2.8 kb) was the correct size
for the c-myb cDNA transcribed from the pRmb3SVneo
expression vector which has eliminated 3' untranslated
sequence.
It was observed by one of us that c-myb transcripts
derived from pRmb3SVneo were translated to various ex-
MOL. CELL. BIOL.
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FIG. 2. Expression of c-myb transcripts by clones transfected
with the pRmb3SVneo or pSV2neo plasmid and from normal
thymocytes. RNA was size fractionated by agarose electrophoresis,
bound to a nitrocellulose filter, and hybridized to the c-myb probe.
The numbers indicate the sizes of the endogenous c-myb transcript
and the c-myb mRNA transcribed from the pRmb3Svneo vector (3.8
and 2.8 kb, respectively). Upper and lower bars represent locations
of the 28S and 18S rRNA markers, respectively.
tents in transfected cells. Thus, it was critical to analyze all
the transfected clones for c-Myb protein levels. Immunopre-
cipitation with an anti-c-Myb antiserum showed that a
pRmb3SVneo-transfected clone, Eli, produced a higher
level of c-Myb protein than all the other clones (Fig. 3).
From densitometric scanning, the quantity of c-Myb protein
in Eli ranged from 8- to 108-fold more than in various
experimental and control clones. At this point, we cannot
rule out the possibility that the c-Myb protein produced by
Eli is derived from the endogenous c-myb transcript. Aside
from Eli, no consistent differences in c-Myb protein levels
were observed between the other experimental and control
samples.
Expression of c-myc proto-oncogene is increased in clone
Eli. A proposed role for the c-Myb protein is gene regula-
tion. We examined the transfected clones for alterations in
the expression of the c-myc and c-fos proto-oncogenes, two
early competence genes that encode proteins which may
play important roles in cell proliferation and transcription
(18, 26, 27, 39, 42, 53). Baseline levels of c-myc were
detected by Northern hybridization in all the clones exam-
ined (Fig. 4). However, clone Eli consistently expressed
greatly enhanced levels of the 2.4-kb c-myc transcript. There
were no detectable c-fos transcripts in any of the clones
(data not shown). Since only one clone produced higher
levels of the c-Myb protein, further investigations described
below were necessary.
Stimulation of c-myc promoter by c-Myb protein. To further
examine the proposed role of c-Myb in c-myc gene regula-
tion, we cotransfected the murine T cell line EL-4 with the
pRmb3SVneo expression vector and pM(Bg)CAT (a plasmid
with the cat reporter gene under the control of the c-myc
promoter [Fig. 1B] [also reference 41]). As a control, pM(Bg)
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FIG. 3. Expression of c-Myb protein from CTLL-2 parent cells
and from clones derived from pRmb3SVneo- or pSV2neo-trans-
fected cells. Cells were metabolically labeled with [35S]methionine,
and cell lysates were prepared. The c-Myb protein was precipitated
with the anti-c-Myb antiserum and analyzed on a sodium dodecyl
sulfate-10% polyacrylamide gel. Numbers to the left refer to the
positions of molecular size markers (kd, kilodaltons). The Myb-
specific antiserum detects a 75-kilodalton protein. Numbers below
each lane represent amounts of c-Myb protein in each clone relative
to that in clone Eli as determined by densitometric scanning.
CAT was cotransfected with pSV2neo (Fig. 5A). This con-
trol yielded a low level of CAT activity that was only slightly
higher than that of pM(Bg)CAT alone. This slight enhance-
ment is most likely due to carrier DNA effects. In the
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FIG. 4. Expression of the c-myc gene by transfectant clones.
Purified RNA was size fractionated by agarose electrophoresis,
bound to a nitrocellulose filter, and hybridized to the c-myc probe.
The location of the 2.4-kb c-myc transcript is indicated. Upper and
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FIG. 5. (A) The trans-activation of the c-myc promoter by the c-Myb protein. The various plasmids used to transfect or to cotransfect
EL-4 cells are shown to the left of the graph. Fold induction was calculated by the following equation: % acetylation of experimental
cotransfection consisting of pRmb3SVneo plus the appropriate cat gene-containing construct/% acetylation of control cotransfection
consisting of pSV2neo plus the appropriate cat-containing construct. Percent acetylation (%Ac) of individual control cotransfection is given
in parentheses. This value is also expressed as 1 on the x axis. Results from four representative experiments are averaged and shown above.
Another seven experiments showed similar results; however, they lacked the pCAT(AEP) control. (B) Frameshift mutant of pRmb3SVneo
does not transactivate the c-myc promoter. EL-4 cells were transfected with the following plasmids: pM(Bg)CAT (lane 1); pM(Bg)CAT plus
pRmb3SVneo (lane 2); pM(BG)CAT plus pJTmyb-fs (lane 3); pSV2CAT plus pRmb3SVneo (lane 4); pSV2CAT plus pJTmyb-fs (lane 5);
pCAT(AEP) plus pRmb3SVneo (lane 6); pCAT(AEP) plus pJTmyb-fs (lane 7).
pRmb3SVneo gave a 10.65-fold induction of CAT activity
over the control cotransfected group. The range of induction
for 11 independent transfections was 8- to 14-fold. Notably,
this high level of induction was reproducibly observed when
the cells were in the log phase but not when they were in the
stationary phase of the cell cycle.
The plasmid pRmb3SVneo was also cotransfected with
pSV2CAT, pAlOCAT, or pCAT(AEP) to determine whether
the trans-acting effects of c-Myb protein are specific for the
c-myc promoter (Fig. 5A). CAT levels produced by
pSV2CAT, pAlOCAT, and pCAT(AEP) in the presence of
pRmb3SVneo were slightly higher than those produced in
the presence of pSV2neo. These results suggest that c-Myb
weakly activates through yet undefined plasmid sequences;
however, the level of activation was very low compared with
activation through the c-myc promoter. The presence of a
single repeat of the SV40 enhancer region in pSV2CAT did
not affect this basal activation. This is in accord with another
report which showed that c-Myb did not trans-activate a
single repeat of the SV40 enhancer but did when multiple
copies were present (38).
As an additional control, a frameshift mutant of
pRmb3SVneo was made. This mutant, pJTmyb-fs, did not
trans-activate the pM(Bg)CAT construct (Fig. SB). This
demonstrates that the production of correct c-Myb transcript
and protein is important in the trans-activation phenomenon
described above.
The basic trend described above has been reproduced in
CTLL-2 in two experiments and in another murine thymoma
line, BW5147 (data not shown).
Elevated c-Myb protein did not alter responses to recombi-
nant IL-2, doubling time, or cell surface phenotypes. Trans-
fected clones were tested for their ability to proliferate to
recombinant IL-2, their doubling time, and surface pheno-
types (data not shown). First, there were slight variations in
the proliferative capacities of various clones for a range of
IL-2; however Eli and the other clones were indistinguish-
able in their ability to respond to IL-2 and their dependency
on IL-2. Second, all the clones including Eli exhibited
similar doubling times ranging from 10 to 12 h. Finally, all
the clones including Eli expressed indistinguishable levels
of differentiation markers, as determined by immunocyto-
fluorometry. These include Thy-1, CD4, CD8, IL-2 receptor,
and T3. Markers that are expressed by lpr T cells which are
detectable by antibodies RA3-3Al, RA3-2C2, 9F3, and 6C3
were also indistinguishable on Eli versus the other clones.
DISCUSSION
In this study, the c-myb gene was introduced into a T-cell
line to examine directly its function in T cells. The effects of
elevated c-Myb protein on the expression of genes proposed
to be involved in cell proliferation and activation, on the
expression of differentiation markers, on proliferation, and
on cell cycle doubling time were determined.
The presumption for examining c-myc is that the myriad
roles attributed to c-Myb may be due to its ability to regulate
other genes which in turn are critical for cell proliferation,
differentiation, or hematopoiesis. In accord with this hypoth-
esis, this analysis showed that a clone which expresses high
levels of c-Myb protein also expresses corollary increases in
c-myc transcripts. Additional cotransfection experiments
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showed that c-Myb trans-activates 1.7 kb of the c-myc
promoter. It is noteworthy that this region of the c-myc
promoter contains one copy of the v-Myb recognition site,
pyAAC(GIT)T. Future site-specific mutagenesis of the con-
sensus v-myb recognition sequence within the c-myc pro-
moter should determine whether this sequence is indeed
important for regulation by the c-Myb protein.
It is noteworthy that the c-Myc protein may also regulate
gene expression, as demonstrated by the ability of the c-Myc
protein to enhance heterologous gene transcription (27, 39).
It is possible that c-myc and c-myb are members of a cascade
or cycle of regulatory genes and that c-myb has pleiotropic
effects on the expression of multiple genes, thus serving as a
master regulatory gene.
Contrary to our finding, Clarke et al. (7) observed that
Friend murine erythroleukemia cells which constitutively
expressed high levels of a transfected c-myb gene exhibited
normal regulation and levels of c-myc. It is very likely that
the effects of c-Myb protein are cell type and differentiation
dependent.
In contrast to c-myc, the expression of c-fos was not
induced. This suggests that the increased c-myc expression
by clone Eli was not due to a general increase in gene
transcription nor to a global activation of regulatory onco-
genes.
The analysis of c-myb-transfected CTLL-2 clones showed
that despite the elevated levels of c-myb and subsequently
c-myc, IL-2 dependency, as well as IL-2-dependent prolif-
eration and cell cycling, have not been altered. In light of
reports that support a role for c-myb and c-myc in cell
proliferation, our findings imply several possibilities. First, it
is likely that certain factors in addition to c-myb and c-myc
are involved in the control of cell division. Second, the low
levels of endogenous c-myb produced by the parent CTLL-2
line may be sufficient to mediate its role in cell proliferation
and cell cycle progression. Third, due to the necessity to
include IL-2 in these studies, it is possible that IL-2 over-
rides some of the effects of the transfected c-myb.
Elevated c-Myb protein also did not affect the expression
of T-cell differentiation markers or induce the expression of
surface markers typical of the abnormal lpr T cells. The Ipr
T cells produce high levels of c-Myb protein, lack the CD4
and CD8 markers of normal mature T cells, and express
markers which are not found on normal peripheral T cells
(12, 35). Our results showed that the presence of high c-Myb
protein alone does not alter the expression of a panel of
differentiation numbers.
In summary, our study showed that a high level of c-Myb
protein in transfected CTLL-2 cells does not appear to affect
cell proliferation or the rate of cell cycle progression. The
surface phenotype of the clone which expressed elevated
c-Myb protein was not different from those of clones which
synthesized much lower levels of the protein. These data
suggest that other factors are involved in addition to, or
exclusive of, c-Myb in the regulation of the above processes.
In contrast, enhanced expression of the c-myb proto-onco-
gene is associated with high c-myc levels. This is the first
demonstration of a c-Myb-mediated regulation of c-myc.
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ADDENDUM IN PROOF
A paper by S. A. Ness et al. (Cell 59:1115) shows that
c-Myb trans-activates the Mim-J gene.
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